PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 107 filers reported holding PMV PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,922,388 | -10.7% | 1,941,757 | -8.9% | 0.00% | 0.0% |
| Q2 2023 | $13,345,200 | +57.0% | 2,131,821 | +19.6% | 0.00% | +50.0% |
| Q1 2023 | $8,500,159 | -29.5% | 1,782,004 | +28.6% | 0.00% | -33.3% |
| Q4 2022 | $12,054,711 | +4.5% | 1,385,599 | +42.9% | 0.00% | 0.0% |
| Q3 2022 | $11,537,000 | -46.9% | 969,498 | -36.4% | 0.00% | -40.0% |
| Q2 2022 | $21,733,000 | +378.5% | 1,525,078 | +599.0% | 0.01% | +400.0% |
| Q1 2022 | $4,542,000 | +22.5% | 218,182 | +35.9% | 0.00% | 0.0% |
| Q4 2021 | $3,709,000 | +391.3% | 160,552 | +533.4% | 0.00% | – |
| Q3 2021 | $755,000 | -82.5% | 25,347 | -80.0% | 0.00% | -100.0% |
| Q2 2021 | $4,326,000 | +1210.9% | 126,635 | +1162.2% | 0.00% | – |
| Q1 2021 | $330,000 | -12.9% | 10,033 | +63.0% | 0.00% | – |
| Q4 2020 | $379,000 | -20.2% | 6,155 | -54.0% | 0.00% | – |
| Q3 2020 | $475,000 | – | 13,375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |